Abstract
The aim of this study was to evaluate the treatment effects with recombinant human growth hormone (rhGH) in a group of patients after bone marrow transplantation for thalassemia major. At the end of treatment we divided the subjects into two groups according to the outcome of the therapy: responder and non-responder. Responder group: after 24 months of rhGH administration, growth rate was still significantly higher in respect to start of treatment (P < 0.0001). plasma levels of igf-i rose significantly (P < 0.003). the serum levels of serum asparate aminotransferase (sgot) and alanine aminotransferase (sgpt) were higher compared to normal values but improved in non-responder patients. there was no difference in the mean concentration of these parameters before and after treatment (P = NS). Non-responder group: these patients had a worsening of the growth rate during rhGH administration. There was no increase of the IGF-I levels. Single values of transaminase and ferritin levels were higher than in responder patients before and after treatment. There was a significant correlation between IGF-I, SGOT, SGPT and ferritin in all patients before and after therapy. It appears from these data that rhGH administration is worth serious consideration in patients after BMT for thalassemia major presenting impaired growth hormone secretion. This treatment can offer good results only in cases where the normal hepatic synthesis of IGF-I is conserved and where liver damage has not reached irreversible conditions, as we have seen in the responder group.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Simone, M., Bartolomeo, P., Olioso, P. et al. Growth after recombinant human growth hormone (rhGH) treatment in transplanted thalassemic patients. Bone Marrow Transplant 20, 567–573 (1997). https://doi.org/10.1038/sj.bmt.1700931
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700931
Keywords
This article is cited by
-
Final height of thalassemic patients who underwent bone marrow transplantation during childhood
Bone Marrow Transplantation (2001)
-
Endocrine complications of thalassemia
Journal of Endocrinological Investigation (2001)
-
Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major
Journal of Endocrinological Investigation (2000)